Blueprint Medicines
BPMC
BPMC was delisted on the 17th of July, 2025.
280 hedge funds and large institutions have $6.29B invested in Blueprint Medicines in 2021 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 98 increasing their positions, 108 reducing their positions, and 35 closing their positions.
3% more capital invested
Capital invested by funds: $6.12B → $6.29B (+$172M)
9% less repeat investments, than reductions
Existing positions increased: 98 | Existing positions reduced: 108
1.45% less ownership
Funds ownership: 101.83% → 100.38% (-1.5%)
3% less funds holding
Funds holding: 288 → 280 (-8)
14% less first-time investments, than exits
New positions opened: 30 | Existing positions closed: 35
20% less call options, than puts
Call options by funds: $9.29M | Put options by funds: $11.7M
25% less funds holding in top 10
Funds holding in top 10: 8 → 6 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$96.6M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
+$41.1M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$29.1M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$18.7M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$18.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$90.3M |
| 2 |
CCM
Cadian Capital Management
New York
|
-$62.9M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$43M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$23.7M |
| 5 |
Goldman Sachs
New York
|
-$22.2M |
BPMC Hedge Fund Activity: Q4 2021 in Review
280 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Blueprint Medicines (BPMC) for Q4 2021, worth a combined $6.29B — up 2.8% from $6.12B a quarter earlier.
Sellers outnumbered buyers: 35 funds closed out of BPMC and 30 opened new positions — a net loss of 5 holders — while 108 trimmed existing stakes and 98 added.
The largest buyer was Marshall Wace, adding an estimated $96.6M. The largest seller was Fidelity Investments, cutting an estimated $90.3M.
- 280 institutional investors held Blueprint Medicines (BPMC) as of Q4 2021, down from 288 in Q3 2021.
- Funds reported $6.29B of Blueprint Medicines stock for Q4 2021, up 2.8% quarter-over-quarter.
- 30 funds opened new Blueprint Medicines positions in Q4 2021 and 35 closed out, a net change of -5 holders.
- The largest Blueprint Medicines buyer in Q4 2021 was Marshall Wace, an estimated $96.6M added.
- The largest Blueprint Medicines seller in Q4 2021 was Fidelity Investments, an estimated $90.3M sold.
Based on aggregated 13F filings for Q4 2021.